Novo Nordisk plans to simultaneously advance the launch of Zenagamtide in both oral and subcutaneous forms

智通财经2026/09/21 10:21

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novo Nordisk's Chief Scientific Officer stated that the company hopes to launch both oral and subcutaneous injection forms of Zenagamtide to the market simultaneously.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novo Nordisk plans to simultaneously advance the launch of Zenagamtide in both oral and subcutaneous forms

You may also like

Crypto prices